Small Molecule vs. Biologic: Tailoring Your Drug Patent LOE Strategy for Generics vs. Biosimilars
Why Your LOE Strategy Depends on Molecule Type A brand-name drug losing its final patent is not one event. It […]
Win the Tender: A Business Development Guide for Biopharma Commercial Vendors Selling Tender Strategy Consulting in EU Markets Timed Around Drug Patent Loss of Exclusivity Dates
Every year, billions of euros in pharmaceutical procurement value shifts from branded drug budgets to competitive tender processes across the
New Drug, Old Molecule: How Pharma Extracts Billions from Mature Drugs Through New Indications
Methods-of-use patents have quietly become the pharmaceutical industry’s most underappreciated exclusivity tool. Here’s how they work, who’s using them, and
Sell to the Drug Patent Cliff: How Biopharma Packaging Companies Win Deals by Tying Serialization and Anti-Counterfeit Solutions to Drug Patent Loss of Exclusivity
The Window You Cannot Miss Every drug patent that expires is a commercial event for at least a dozen industries.
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value
The FDA lets you extend only one patent per drug approval. Most companies leave years of exclusivity on the table
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know
There is a persistent gap between what Western pharmaceutical executives think they know about drug patent protection in Eurasia and
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
The Art of the Design-Around: Analyzing Drug Formulation Patent Claims to Mitigate Infringement Risk
A Strategic Guide for Pharmaceutical IP Professionals, Formulation Scientists, and Generic Drug Developers Introduction: Why Patent Claims Decide Who Wins
Patent Term Restoration vs. Adjustment: The $300 Billion Clock Pharma Can’t Afford to Misread
Every pharmaceutical patent starts its life with a 20-year timer running from the filing date. By the time a new
Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives
Every patent portfolio in the pharmaceutical industry contains dead weight. Not metaphorically — literally. Compounds whose commercial logic evaporated years
